Irina Perjar
University of North Carolina at Chapel Hill
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Irina Perjar.
The Journal of Rheumatology | 2014
Imran Aslam; Irina Perjar; Xiaoyan A. Shi; Jordan B. Renner; Virginia B. Kraus; Yvonne M. Golightly; Joanne M. Jordan; Amanda E. Nelson
Objective. To determine the associations between joint metabolism biomarkers and hand radiographic osteoarthritis [(rOA), based on Kellgren Lawrence (KL) grade ≥ 2], symptoms, and function. Methods. Cross-sectional data were available for 663 participants (mean age 63 yrs, 63% white, 49% women). Three definitions of hand rOA were considered: (1) a composite measure involving at least 3 hand joints distributed bilaterally with 2 of 3 in the same joint group, including ≥ 1 distal interphalangeal joint, without metacarpophalangeal (MCP) swelling; (2) rOA in at least 1 joint of a group; and (3) number of joints with KL ≥ 2. We assessed hand symptoms and the 15-item Australian Canadian Hand Osteoarthritis Index (AUSCAN; Likert format). We measured serum cartilage oligomeric matrix protein (sCOMP), hyaluronic acid (sHA), carboxy-terminal propeptide of type II collagen, type II collagen degradation product, urinary C-terminal crosslinked telopeptide of type II collagen, and urinary N-terminal crosslinked telopeptide. Linear regression models were performed to assess associations between each biomarker with hand rOA, AUSCAN, and symptoms, adjusting for age, sex, race, current smoking/drinking status, body mass index, and hip and knee rOA. Results. In adjusted analyses, MCP (p < 0.0001) and carpometacarpal rOA (p = 0.003), and a higher number of hand joints with rOA (p = 0.009), were associated with higher levels of sHA. Positive associations were seen between AUSCAN and hand symptoms and levels of sCOMP (p ≤ 0.003) and sHA (p ≤ 0.048). Conclusion. Hand symptoms and higher AUSCAN scores were independently associated with higher levels of both sCOMP and sHA; hand rOA was associated only with sHA levels.
Clinical Gastroenterology and Hepatology | 2017
Craig C. Reed; W. Asher Wolf; Cary C. Cotton; Spencer Rusin; Irina Perjar; Johnathan Hollyfield; John T. Woosley; Nicholas J. Shaheen; Evan S. Dellon
BACKGROUND AND AIMS: No prospective studies substantiate 15 eos/hpf as an appropriate endpoint for treatment of eosinophilic esophagitis (EoE). We aimed to determine a histologic cutpoint that identifies successful treatment of EoE by assessing symptomatic and endoscopic improvement. METHODS: We performed a prospective cohort study of 62 consecutive adult patients undergoing outpatient esophagogastroduodenoscopy at the University of North Carolina from 2009 through 2014. At diagnosis of EoE and after 8 weeks of standard treatment, symptom and endoscopic responses were measured using a visual analogue scale and an endoscopic severity score (ESS), and eosinophil counts were assessed. Receiver operator curves and logistic regression models evaluated the histologic threshold that best predicted symptomatic and endoscopic response. For symptoms, analysis was limited to patients without baseline esophageal dilation. RESULTS: The mean eosinophil count at diagnosis was 124 eos/hpf, falling to 35 eos/hpf after treatment. The mean visual analogue scale decreased from 3.4 at baseline to 1.7 after treatment, and the mean ESS decreased from 3 to 1.6. Twenty‐nine patients had symptom responses (47%) and 34 had endoscopic responses (55%). Post‐treatment eosinophil count thresholds of 8, 15, and 5 eos/hpf best predicted symptom, endoscopic and combined responses, respectively. On logistic regression, decreasing eosinophil count was significantly associated with the probability of symptomatic (P = .01) and endoscopic response (P < .001). CONCLUSIONS: In a prospective study of patients with EoE, we found that a cutpoint of <15 eos/hpf identifies most patients with symptom and endoscopic improvements, providing support for the current diagnostic threshold. A lower threshold (<5 eos/hpf) identifies most patients with a combination of symptom and endoscopic responses; this cutpoint might be used in situations that require a stringent histologic threshold.
Human Pathology | 2017
Spencer Rusin; Shannon Covey; Irina Perjar; Johnny Hollyfield; Olga Speck; Kimberly Woodward; John T. Woosley; Evan S. Dellon
Many studies of eosinophilic esophagitis (EoE) use expert pathology review, but it is unknown whether less experienced pathologists can reliably assess EoE histology. We aimed to determine whether trainee pathologists can accurately quantify esophageal eosinophil counts and identify associated histologic features of EoE, as compared with expert pathologists. We used a set of 40 digitized slides from patients with varying degrees of esophageal eosinophilia. Each of 6 trainee pathologists underwent a teaching session and used our validated protocol to determine eosinophil counts and associated EoE findings. The same slides had previously been evaluated by expert pathologists, and these results comprised the criterion standard. Eosinophil counts were correlated, and agreement was calculated for the diagnostic threshold of 15 eosinophils per high-power field as well as for associated EoE findings. Peak eosinophil counts were highly correlated between the trainees and the criterion standard (ρ ranged from 0.87 to 0.92; P<.001 for all). Peak counts were also highly correlated between trainees (0.75-0.91; P<.001), and results were similar for mean counts. Agreement was excellent for determining if a count exceeded the diagnostic threshold (κ ranged from 0.83 to 0.89; P<.001). Agreement was very good for eosinophil degranulation (κ = 0.54-0.83; P<.01) and spongiosis (κ = 0.44-0.87; P<.01) but was lower for eosinophil microabscesses (κ = 0.37-0.64; P<.01). In conclusion, using a teaching session, digitized slide set, and validated protocol, the agreement between pathology trainees and expert pathologists for determining eosinophil counts was excellent. Agreement was very good for eosinophil degranulation and spongiosis but less so for microabscesses.
Clinical Gastroenterology and Hepatology | 2018
Swathi Eluri; Sara R. Selitsky; Irina Perjar; Johnathan Hollyfield; Renee Betancourt; Cara Randall; Spencer Rusin; John T. Woosley; Nicholas J. Shaheen; Evan S. Dellon
BACKGROUND & AIMS Few factors have been identified that can be used to predict response of patients with eosinophilic esophagitis (EoE) to topical steroid treatment. We aimed to determine whether baseline clinical, endoscopic, histologic, and molecular features of EoE can be used to predict histologic response. METHODS We collected data from 97 patients with EoE, from 2009 through 2015, treated with a topical steroid for 8 weeks; 59 patients had a histologic response to treatment. Baseline clinicopathologic features and gene expression patterns were compared between patients with a histologic response to treatment (<15 eos/hpf) and non‐responders (≥15 eos/hpf). We performed sensitivity analyses for alternative histologic response definitions. Multivariate logistic regression was performed to identify predictive factors associated with response to therapy, which were assessed with area under the receiver operator characteristic (AUROC) curves. RESULTS Baseline dilation was the only independent predictor of non‐response (odds ratio [OR], 0.30; 95% CI, 0.10–0.89). When an alternate response (<1 eos/hpf) and non‐response (<50% decrease in baseline eos/hpf) definition was used, independent predictors of response status were age (OR, 1.08; 95% CI, 1.02–1.14), food allergies (OR, 12.95; 95% CI, 2.20–76.15), baseline dilation (OR, 0.17; 95% CI, 0.03–0.88), edema or decreased vascularity (OR, 0.20; 95% CI, 0.04–1.03), and hiatal hernia (OR, 0.07; 95% CI, 0.01–0.66). Using these 5 factors, we developed a predictive model that discriminated complete responders from non‐responders with an AUROC of 0.88. Baseline gene expression patterns were not associated with treatment response and did not change with different histologic response thresholds. CONCLUSIONS In an analysis of 97 patients with EoE, we found dilation to be the only baseline factor associated with non‐response to steroid treatment (<15 eos/hpf). However, a model comprising 5 clinical, endoscopic, and histologic factors identified patients with a complete response (<1 eos/hpf). A baseline gene expression panel was not predictive of treatment response at any threshold.
Allergy | 2018
Manaswita Tappata; Swathi Eluri; Irina Perjar; Johnathan Hollyfield; Renee Betancourt; Cara Randall; John T. Woosley; Joshua B. Wechsler; Evan S. Dellon
associated with mutations and gene expression differences of ORMDL genes that can interact. Allergy. 2015;70:1288-1299. 8. Schmiedel BJ, Seumois G, Samaniego-Castruita D, et al. 17q21 asthma-risk variants switch CTCF binding and regulate IL-2 production by T cells. Nat Commun. 2016;7:13426. 9. Bisgaard H, Bønnelykke K, Sleiman PMA, et al. Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med. 2009;179:179185.
Diseases of The Esophagus | 2018
Nathaniel T. Koutlas; Swathi Eluri; Spencer Rusin; Irina Perjar; Johnathan Hollyfield; John T. Woosley; Nicholas J. Shaheen; Evan S. Dellon
Gastroenterology | 2017
Swathi Eluri; Sara R. Selitsky; Joel S. Parker; Johnathan Hollyfield; Irina Perjar; Spencer Rusin; John T. Woosley; Richard H. Lash; Robert M. Genta; Evan S. Dellon
Gastroenterology | 2018
Manaswita Tappata; Swathi Eluri; Irina Perjar; Johnathan Hollyfield; Renee Betancourt; Cara Randall; John T. Woosley; Joshua B. Wechsler; Evan S. Dellon
Gastroenterology | 2018
Swathi Eluri; Renee Betancourt; Cara Randall; Irina Perjar; Johnathan Hollyfield; John T. Woosley; Nicholas J. Shaheen; Evan S. Dellon
Gastrointestinal Endoscopy | 2017
Swathi Eluri; Irina Perjar; Johnathan Hollyfield; Spencer Rusin; John T. Woosley; Nicholas J. Shaheen; Evan S. Dellon